These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Cardiac metastasis from renal cell carcinoma successfully treated with pazopanib: impact of TKIs' antiangiogenic activity. Schinzari G; Monterisi S; Signorelli D; Cona MS; Cassano A; Danza F; Barone C Tumori; 2014; 100(6):e298-300. PubMed ID: 25688515 [TBL] [Abstract][Full Text] [Related]
5. Good tolerability, long-term survival and easy management of side effects in a patient with metastatic renal cell carcinoma treated with pazopanib. Frascaroli M; Di Cesare P Tumori; 2014; 100(6):e301-4. PubMed ID: 25688516 [TBL] [Abstract][Full Text] [Related]
6. [Tyrosine kinase inhibitor as adjuvant treatment of renal cell carcinoma: 1 versus 3]. Penel N Bull Cancer; 2017 Sep; 104(9):705-706. PubMed ID: 28760312 [No Abstract] [Full Text] [Related]
7. Pazopanib: an oral multitargeted tyrosine kinase inhibitor for use in renal cell carcinoma. LaPlant KD; Louzon PD Ann Pharmacother; 2010 Jun; 44(6):1054-60. PubMed ID: 20407031 [TBL] [Abstract][Full Text] [Related]